Compare J B Hunt Transport Services Inc (JBHT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J B Hunt Transport Services Inc vs TG Therapeutics Inc — how do they compare? J B Hunt Transport Services Inc trades at $229.59 (market cap $21.45B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: J B Hunt Transport Services Inc is far larger — about 2.6× TG Therapeutics Inc's market cap, and J B Hunt Transport Services Inc pays a 0.79% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold J B Hunt Transport Services Inc for 46 Days and TG Therapeutics Inc for 16 Days on average.
| JBHT | TGTX | |
|---|---|---|
Market Cap | $21.45B | $8.16B |
Volume | 1,028,680 | 1,735,121 |
Sector | Industrials | Health |
52-Week High | $298.41 | $59.06 |
52-Week Low | $137.09 | $26.94 |
Typical Hold Time | 46 Days | 16 Days |
Enterprise Value | $22.59B | $8.37B |
Dividend Yield | 0.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBHT trades at $229.26, up 2.97% today, amid a bearish technical signal but strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue has stabilized around $12B, while profitability metrics like ROE (18.45%) and net margin (5.31%) remain solid. However, rising costs and ongoing securities litigation investigations present headwinds.
The outlook is mixed: Wall Street's consensus price target of $289.40 implies significant upside, but near-term pressure from fuel costs and legal overhangs may limit gains. Investors should weigh strong fundamentals against operational risks and market sentiment shifts ahead of Q3 earnings.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
